BeyondSpring Q1 net loss $2.4M from continuing ops; cash $7.9M; AACR data supports Plinabulin-ADC combo

BeyondSpring Inc.

Net loss from continuing operations $2.4M vs $2.6M YoY; discontinued ops loss $4.3M.
Cash and short-term investments $7.9M as of March 31, 2026.
AACR 2026 data: Plinabulin enhances efficacy/tolerability of topoisomerase inhibitor–based ADC regimens.
ST-01156 (RBM39 degrader) advanced to Phase 1; first dose cohort completed.
SEED's operations reported as discontinued due to planned sale of preferred shares.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

BeyondSpring Inc. reported the quarter ended March 31, 2026 results: net income Net loss was $2.4 million.

Period: the quarter ended March 31, 2026
Net income: Net loss was $2.4 million
Result: reported results

Exact text from the filing

On May 13, 2026, BeyondSpring Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

BeyondSpring Inc. filing history →

Source: SEC EDGAR

accession 0001171843-26-003344

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.